Sir, The incidence of infections caused by pneumococci resistant to penicillin has increased at an alarming rate during the past two decades. In Europe, the highest incidences of resistance to penicillin among clinical isolates of Streptococcus pneumoniae have been recorded in France, Spain and the Slovak Republic.
levofloxacin intermediate (MIC 4 mg/L). According to the recently proposed breakpoints for S. pneumoniae (resistant: у4 mg/L), all strains in this study were susceptible to gatifloxacin. 4 The present study demonstrated excellent in vitro activity of gatifloxacin against clinical S. pneumoniae isolates. In a recent international surveillance study, the in vitro activity of gatifloxacin, penicillin, erythromycin and four other peer drugs was tested against 2284 pneumococcal strains isolated in 1997 in Canada, the USA, six Latin American countries and Europe. Gatifloxacin demonstrated uniform potency against pneumococci across all monitored geographical areas (MIC 90 0.5 mg/L).
5 Nevertheless, wider usage of this class of antibiotics may result in a change of the present excellent resistance situation in pneumococci. 6 These data indicate that the resistance of S. pneumoniae to newer fluoroquinolones should be carefully monitored and underscore the risk of uncritical and broad usage of these antibiotics undermining the excellent resistance situation in the near future. 
